Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Total Current Liabilities (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Total Current Liabilities for 4 consecutive years, with $106.6 million as the latest value for Q4 2022.

  • On a quarterly basis, Total Current Liabilities rose 9.22% to $106.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $106.6 million, a 9.22% increase, with the full-year FY2022 number at $112.9 million, up 15.7% from a year prior.
  • Total Current Liabilities was $106.6 million for Q4 2022 at NovaBridge Biosciences, up from $97.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $106.6 million in Q4 2022 to a low of $83.5 million in Q4 2019.
  • A 4-year average of $93.7 million and a median of $92.3 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: increased 4.12% in 2020, then rose 12.27% in 2021.
  • NovaBridge Biosciences' Total Current Liabilities stood at $83.5 million in 2019, then increased by 4.12% to $86.9 million in 2020, then rose by 12.27% to $97.6 million in 2021, then rose by 9.22% to $106.6 million in 2022.
  • Per Business Quant, the three most recent readings for NBP's Total Current Liabilities are $106.6 million (Q4 2022), $97.6 million (Q4 2021), and $86.9 million (Q4 2020).